Clinical Phase Articles & Analysis
41 articles found
CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. Patient-specific cell collection, genetic modification, and reinfusion introduce high costs, long timelines, and scalability challenges. To address these barriers, in vivo CAR-T has emerged as a new strategy—engineering ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for ...
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. This means that approximately $60 billion dollars are spent annually on unsuccessful drugs.1,2 Contributing to these unchecked costs ...
Drug development is a complex and multifaceted process that involves extensive research and testing to ensure safety, efficacy and quality for human use. One critical element in the drug development process is drug metabolism and pharmacokinetics (DMPK), which refers to how a drug is absorbed, distributed, metabolized, and excreted (ADME) from the body. In vitro DMPK services, along with ...
Drug development is a complex and multifaceted process that involves extensive research and testing to ensure safety, efficacy and quality for human use. One critical element in the drug development process is drug metabolism and pharmacokinetics (DMPK), which refers to how a drug is absorbed, distributed, metabolized, and excreted (ADME) from the body. In vitro DMPK services, along with ...
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the occurrence of many tumors and poor prognosis. It is a very popular ADC research target, second only to HER2. Currently, only Gilead's Trop-2 ADC drug Trodelvy has been approved for ...
What Are the Advantages of Single-Cell RNA Sequencing? One of the significant advantages of scRNA-seq in drug discovery is its impact on target identification. By allowing researchers to dissect complex tissues and diseases at the cellular level, scRNA-seq enables the identification of distinct cell subtypes and their gene expression profiles. This information can lead to a better understanding ...
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. ...
Advantages of Single-Cell RNA Sequencing in Drug Discovery Single-Cell RNA Sequencing (scRNA-seq) offers several advantages in drug discovery, primarily through target identification. By analyzing complex tissues and diseases at the cellular level, scRNA-seq allows researchers to identify distinct cell subtypes and their gene expression profiles. This knowledge enhances our understanding of ...
PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, when Crews' team tested the possibility of artificially induced intracellular protein degradation with a peptide that was too large in molecular weight and required cells to penetrate the peptide to improve cell permeability. The discovery of the first small molecule PROTAC and the ...
At the end of the year 2019, a cluster of severe pneumonia of unknown cause was described in Wuhan (Eastern China) and a SARS-like acute respiratory distress syndrome (ARDS) was noted in these patients. Early in January 2020, sequencing revealed a novel coronavirus (now termed SARS-CoV-2) as the causal factor for the disease designated as COVID-19. The pandemic caused by the virus has unforeseen ...
ByNuvonis
The attached is the transcript of an interview conducted by the Wall Street Analyzer with Paul Ramsay, President of CanaQuest Medical Corp. and posted on the Wall Street Analyzer’s website on January 5, 2023. Additionally, the full interview can be listened to on the Wall Street Analyzer’s website - Canaquest Medical Corp (OTC: CANQF) | The Wall Street Analyzer Interview Notes: 1. ...
The first-in-human case using the new deep vein thrombosis (DVT) device Vetex thrombectomy catheter (Vetex Medical) has recently been completed in a multicentre study. The device has the potential to reduce hospital stays and costs associated with DVT treatment, a press release announces. According to Vetex Medical, the Vetex thrombectomy catheter is the first device to combine rotational and ...
Today marks a historic day for all the scientists and researchers who have dedicated their lives to advancing our understanding of Alzheimer’s Disease over the last 20 years. For the more than 6 million individuals living with Alzheimer’s disease in the US, their families, and their caretakers, our team at Altoida celebrates the positive topline data reported on the CLARITY AD global ...
Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It is ...
Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disease clinically manifested by cognitive impairment, behavioral abnormalities, and social deficits. It is predicted that by 2050, the number of people 65 and older with dementia in the United States could reach 13.8 million. In China, more than 15.07 million elderly people aged 60 or over suffer from dementia, of which ...
Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 – MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine ...
The Barbara Ann Karmanos Cancer Center, located in midtown Detroit, is the only National Cancer Institute (NCI)-designated comprehensive cancer center in metro Detroit and one of just 51 centers of its kind in the United States. The comprehensive cancer center designation means patients can access treatments exclusive to Karmanos, as well as clinical trials, cancer prevention programs, and ...
Gene editing technology, represented by CRISPR/Cas9, has greatly accelerated the development of gene therapy, bringing hope to many genetic diseases that otherwise had no cure. In June 2021, Intellia Therapeutics' NTLA-2001, a CRISPR gene editing therapy for the treatment of transthyretin amyloidosis (ATTR) invented by Nobel Laureate Jennifer Doudna, was proven to be safe and effective in a ...
Ensitrelvir (code name S-217622, brand name Xocova), is a new inhibitor of the SARS-CoV-2 major protease (Mpro), also known as 3C-like protease, has been shown to reduce the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters. In cells, low nanomolar to sub-micromolar doses of Ensitrelvir suppress viral growth. In hamsters, oral treatment of Ensitrelvir showed excellent ...